Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial - MaaT Pharma

Download the poster

Previous PostStifel European Healthcare Summit Lyon
Next PostMay 29, 2024: MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club